NICE to re-evaluate osteoporosis guidance after legal challenge

NICE guidance on osteoporosis will have to be re-evaluated after the High Court ruled that the institute had acted unlawfully in developing the guidance.

The guidance used an economic model which NICE was given in confidence. More effort should have been made to make the model available for public scrutiny, Mr Justice Holman said.

The ruling has been welcomed by the National Osteoporosis Society. It said the decision would provide the opportunity to prove the economic model NICE used was flawed.

Servier Laboratories challenged NICE at judicial review because it believed the guidance unfairly restricted access to its drug Protelos (strontium ranelate).

Comment below and tell us what you think


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in